Lamivudine / Zidovudine ViiV H-W-672

  • Email
  • Help
Name of the medicinal productLamivudine / Zidovudine ViiV (previously Lamivudine / Zidovudine GSK)
Opinion holderViiV Healthcare UK Limited
Greenford Road
Greenford, Middlesex UB6 0NN
United Kingdom
Active substanceLamivudine / zidovudine
International non-proprietary name or common nameLamivudine / zidovudine
Pharmaco-therapeutic groupAntivirals for systemic use
ATC codeJ05AR01
Therapeutic indicationLamivudine/zidovudine is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (HIV) infected adults and children.
Orphan medicinal product designation dateNot applicable

This medicine was previously called: Lamivudine/Zidovudine GSK

Back to top

Document(s) Language Status First published Last updated Effective Date
Lamivudine/Zidovudine ViiV : Public statement - Cessation of manufacture (English only)   2015-12-21    
Lamivudine / Zidovudine ViiV : Summary for the public (English only)   2009-04-28 2015-12-21  
Lamivudine / Zidovudine ViiV : All presentations (English only)   2009-04-28 2015-12-21  
Lamivudine / Zidovudine ViiV : Scientific discussion (English only)   2009-04-28 2015-12-21  
Lamivudine / Zidovudine ViiV : Procedural steps taken before opinion (English only)   2009-04-28 2015-12-21  
Lamivudine / Zidovudine ViiV : Procedural steps taken and scientific information after opinion (English only)   2009-04-28 2015-12-21  
Lamivudine / Zidovudine ViiV : Lamivudine / Zidovudine GSK-H-W-672-II-0011 - Scientific discussion (English only)   2009-04-28 2015-12-21  

17/09/2015 Lamivudine / Zidovudine GSK-H-W-672-WS-0755

Back to top

Document(s) Language Status First published Last updated Effective Date
Lamivudine / Zidovudine ViiV : Product information (English only)   2009-04-28 2015-12-21  

Related links

*This document includes:

Annex I - Summary of product characteristics
Annex IIA - Manufacturer responsible for batch release
Annex IIB - Recommendations to the opinion holder - conditions of use
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.